Fed’s Powell opens door to potential rate cuts at Jackson Hole
Jean F. Holloway, Senior Vice President and General Counsel at Artivion Inc. (NYSE:AORT), recently sold shares of the company’s common stock valued at approximately $145,677. The transactions occurred on February 24, 2025, with shares sold at a price of $27.306 each. The sale comes amid recent market volatility, with the stock experiencing a 13% decline over the past week, though analysts maintain bullish targets ranging from $32 to $35 per share.
The sales were made to cover tax withholding obligations upon the vesting of restricted stock units and do not represent discretionary transactions. Following these sales, Holloway retains ownership of 149,799 shares in Artivion, a medical device company currently valued at $1.06 billion. According to InvestingPro, the company maintains a GOOD financial health score, with 10+ additional exclusive insights available to subscribers.
In other recent news, Artivion Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $97.3 million, which did not meet the forecasted $100.82 million. This shortfall was primarily due to a cybersecurity incident that impacted sales by approximately $4.5 million. Despite this, Artivion’s adjusted EBITDA for the quarter exceeded expectations, reaching $17.6 million compared to an anticipated $17 million. Analysts from Stifel and Needham have adjusted their price targets for Artivion, with Stifel lowering its target to $30 and Needham to $32, both maintaining a Buy rating on the stock. JMP Securities, however, maintained its $33 price target and Market Outperform rating, highlighting the company’s resilience despite the cyber incident. Artivion’s management projects a recovery in sales growth throughout 2025, with expected revenues between $420 million and $435 million, aligning with previous estimates. The company also forecasts its 2025 adjusted EBITDA to be between $83 million and $91 million, which is favorable compared to prior projections. Notably, Artivion experienced significant growth in its On-X line and stent grafts, with a 10% and 8% increase, respectively, in constant currency terms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.